Psilocybin Case Study Shows Potential for Alzheimer's Symptom Improvement
A case study published in Frontiers in Neuroscience reports that a single high dose of psilocybin, a psychedelic compound found in magic mushrooms, led to significant temporary improvements in an 80-year-old Japanese-American woman with advanced Alzheimer's disease. The patient, diagnosed 10 years prior, had experienced severe cognitive and physical decline over the last five years. After ingesting 5 grams of the Enigma psilocybin strain, she entered a deep sleep-like state for several hours, then emerged with markedly increased alertness and began speaking in autobiographical detail. Over the following weeks, her working memory returned, she regained bladder control, walked more independently, dressed herself, and showed improved social engagement. A smaller dose one month later yielded similar benefits. The study suggests that some brain functions may remain dormant even in late-stage neurodegeneration and could be temporarily reawakened by psilocybin. While limited to a single patient, the findings open avenues for further research into psychedelic therapies for Alzheimer's.
Key facts
- Study published in Frontiers in Neuroscience in June 2026.
- Subject: Japanese-American woman in her 80s with Alzheimer's diagnosed 10 years prior.
- Patient received 5 grams of Enigma psilocybin strain.
- After 19 hours, patient showed improved alertness and autobiographical speech.
- Improvements included working memory, bladder control, mobility, and social engagement.
- A smaller dose one month later produced similar positive effects.
- Patient reported a vision of surfing with her son on a peaceful island.
- Study suggests dormant brain functions may be accessible under psilocybin.
Entities
Institutions
- Frontiers in Neuroscience